Nystatin Powder Dosing Regimen
For mild oropharyngeal candidiasis, use nystatin suspension (100,000 U/mL) at 4–6 mL four times daily, OR nystatin pastilles (200,000 U each) 1–2 pastilles four times daily, for 7–14 days 1.
Oropharyngeal Candidiasis (Oral Thrush)
Mild Disease
- Nystatin suspension (100,000 U/mL): 4–6 mL four times daily for 7–14 days 1
- Nystatin pastilles (200,000 U each): 1–2 pastilles four times daily for 7–14 days 1
The 2016 IDSA guidelines provide strong recommendation with moderate-quality evidence for these regimens. Note that nystatin is positioned as an alternative to clotrimazole troches or miconazole buccal tablets for mild disease, but remains a viable first-line option when azoles are not preferred.
Important Considerations
- Swish and swallow technique: Patients should retain the suspension in the mouth as long as possible before swallowing to maximize contact time with oral mucosa
- Denture-related candidiasis: Disinfection of dentures is mandatory in addition to antifungal therapy 1
- Moderate to severe disease: Nystatin is NOT recommended; use oral fluconazole 100–200 mg daily instead 1
Neonatal Prophylaxis (Prevention of Invasive Candidiasis)
Very Low Birth Weight Infants (<1500 g)
Nystatin suspension: 1 mL (100,000 U) every 8 hours during the high-risk period 2
The 2012 ESCMID guidelines provide a B-II recommendation for oral nystatin in neonates <1500 g. This reflects moderate evidence quality with concerns about potential necrotizing enterocolitis (NEC) risk from inadvertent gut epithelial damage in premature infants.
Alternative Dosing from Research Evidence
- 150,000 U three times daily for 14–21 days in at-risk newborns 3, 4
- 100,000 U every 8 hours for 6 weeks in extremely low birth weight (ELBW) and very low birth weight (VLBW) infants 5, 6, 7
Recent high-quality evidence from 2024 demonstrates that oral nystatin (100,000 U every 8 hours) is equally effective as intravenous fluconazole for preventing systemic fungal infections in VLBW infants, with the advantage of easier administration and lower cost 7. A 2022 meta-analysis confirms substantial reduction in fungal colonization (RR=0.34) and invasive fungal infection (RR=0.15) with nystatin prophylaxis 8.
Timing and Duration
- Start: Within first 72 hours of life or at one week of age after baseline cultures 5, 6
- Duration: Continue for 14–21 days or up to 6 weeks depending on risk factors 2, 5, 6
- Monitoring: Obtain baseline urine culture and rectal swab, then weekly thereafter 5
Product Formulations
Available Concentrations
- Oral suspension: 100,000 units per mL 9
- Contains: Alcohol 0.5–1% v/v 9
- Storage: 20°–25°C (68°–77°F); avoid freezing 9
- Administration: Shake well before using 9
Package Sizes
Critical Pitfalls to Avoid
Do not use nystatin for moderate-to-severe oropharyngeal candidiasis: Fluconazole is superior and strongly recommended 1
Do not use nystatin for esophageal candidiasis: Systemic therapy with fluconazole or echinocandins is always required 1
NEC risk in premature infants: The fragile gut epithelium of ELBW infants may be damaged by oral antifungals, potentially causing necrotizing enterocolitis. This concern led to the B-II (rather than A-I) grading despite efficacy data 2
Heterogeneous distribution: Nystatin distributes unevenly in the gastrointestinal tract and is excreted discontinuously, requiring consistent dosing every 8 hours 4
Resistance concerns with alternatives: Miconazole oral gel is NOT recommended (D-II) due to potential development of triazole resistance that may preclude subsequent fluconazole use 2
No impact on mortality: While nystatin reduces colonization and invasive candidiasis rates in neonates, it does not significantly reduce mortality 2, 7, 8